Kanebo notifies CFDA of the recall of some cosmetic whitening products containing RHODODENDROL
5th Jul 2013, Kanebo has notified the China Food and Drug Administration (CFDA) of the recall of some whitening cosmetics containing RHODODENDROL (Chemical name: 4-(p-hydroxyphenyl) butan-2-ol ; CAS: 69617-84-1). One week ago, Kanebo claimed 54 skin-whitening products across Asia except Chinese market due to adverse effects found & customer complaints. Kanebo claimed that those re-called products have never been sold on Chinese market.
The CFDA has verified Kanebo’s statement and said that Kanebo submitted an application of new cosmetic ingredient approval for RHODODENDROL previously. However, the ingredient did not pass safety assessment and none of cosmetics containing RHODODENDROL has ever been approved by CFDA.
The CFDA has communicated with Kanebo and recognized Kanebo’s efforts in view of submitting the report without delay. Meanwhile the CFDA requests Kanebo to strengthen the safety assessment of new cosmetic products and the post-market monitor of adverse effects.
CIRS's Comments
New cosmetic ingredient registration embodies the Chinese unique style of ingredient management. It can be very complicated to get an approval. Nevertheless, the Kanebo issue proves that this kind of ingredient management sometimes makes sense.
Reference
Contact Us
If you would like to obtain the final or draft version of IECIC or would like to check if your substance is approved for use in cosmetics in China, please contact:
Ms April Guo, CIRS China
Specialized field: application for hygiene License, record-keeping certificate for imported cosmetics, safety evaluation of cosmetics and cosmetic ingredients, standard labelling for cosmetics, SDFA registration, CIQ label, etc.
- Ms April Guo, China Office
11F Building 1, Dongguan Hi-Tech Park, 1288 Chunbo Road, Binjiang District, Hangzhou 310052, China
Tel: +86-571 8720 6555 | Fax: +86-571 8720 6533
Email: april.guo@cirs-reach.com
To follow more events, free regulatory updates and publications from CIRS, please subscribe our monthly newsletter:
